Replimune Group, Inc.

REPLNASDAQHealthcare● Active

$8.97

$-0.50(-5.28%)

Market Cap$740676392

P/E Ratio—

52W High$13.24

52W Low$1.5

Avg Volume7.3M

Open$9.20

Beta0.91

Free Cash Flow Financials Revenue

Replimune Group, Inc. (REPL) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

REPL · free cash flow · updated Jun 8, 2026

Core FCF metrics

REPL · FCF · TTM · margin & CAGR

Free cash flow was −$198.9M for FY2025 (fiscal year ending 2025-03-31), down 4.1% year-over-year

FY2025 Free Cash Flow−$198.9M▼ -4.1% YoY

Trailing 12M (TTM)−$283.3Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

REPL · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$192.3M(7M)−$198.9M▼ 4.1%—

FY2024−$185.5M(6M)−$191.1M▼ 46.7%—

FY2023−$128.1M(2M)−$130.3M▼ 54.2%—

FY2022−$82.2M(2M)−$84.5M▼ 32.5%—

FY2021−$61.4M(2M)−$63.8M▲ +4.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

REPL · P/FCF · FCF yield · FCF per share

Replimune Group, Inc. (REPL) reported negative free cash flow of −$0.20B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-03-31

Cash flow statement summary

REPL · cash flow statement · operating / investing / financing

For FY2025, Replimune Group, Inc. generated −$192.3M in operating cash flow and spent 7M in capital expenditures, yielding −$198.9M in free cash flow.

Operating Activities

−$192.3M

Cash from core business operations

2025-03-31

Investing Activities

−$23.8M

CapEx, acquisitions & investments

2025-03-31

Financing Activities

+$252.4M

Buybacks, dividends & debt

2025-03-31

FCF FormulaOperating CF (−$192.3M) − |CapEx| (7M) = FCF (−$198.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

REPL vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Replimune Group, Inc.YOU

REPL

−$198.9M-4.1%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Replimune Group, Inc. (REPL) reported free cash flow of −$198.9M for FY2025 (fiscal year ending 2025-03-31), down 4.1% year-over-year.

Replimune Group, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

REPL free cash flow · 8 questions

Replimune Group, Inc. free cash flow was −$198.9M for FY2025, down 4.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$283.3M.

REPL free cash flowREPL FCFREPL FCF 2025REPL free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Replimune Group, Inc. · Replimune Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026